



## OPEN ACCESS

APPROVED BY  
Frontiers Editorial Office,  
Frontiers Media SA, Lausanne,  
Switzerland

\*CORRESPONDENCE  
Frontiers Production Office,  
production.office@frontiersin.org

SPECIALTY SECTION  
This article was submitted to Molecular  
and Cellular Oncology,  
a section of the journal  
Frontiers in Cell and Developmental  
Biology

RECEIVED 19 October 2022  
ACCEPTED 19 October 2022  
PUBLISHED 03 November 2022

CITATION  
Frontiers Production Office (2022),  
Erratum: The role and therapeutic value  
of syndecan-1 in cancer metastasis and  
drug resistance.  
*Front. Cell Dev. Biol.* 10:1074502.  
doi: 10.3389/fcell.2022.1074502

COPYRIGHT  
© 2022 Frontiers Production Office.  
This is an open-access article  
distributed under the terms of the  
[Creative Commons Attribution License  
\(CC BY\)](#). The use, distribution or  
reproduction in other forums is  
permitted, provided the original  
author(s) and the copyright owner(s) are  
credited and that the original  
publication in this journal is cited, in  
accordance with accepted academic  
practice. No use, distribution or  
reproduction is permitted which does  
not comply with these terms.

# Erratum: The role and therapeutic value of syndecan-1 in cancer metastasis and drug resistance

Frontiers Production Office\*

Frontiers Media SA, Lausanne, Switzerland

## KEYWORDS

syndecan-1, metastasis, drug resistance, therapy, cancer

## An Erratum on

### The role and therapeutic value of syndecan-1 in cancer metastasis and drug resistance

by Guo S, Wu X, Lei T, Zhong R, Wang Y, Zhang L, Zhao Q, Huang Y, Shi Y and Wu L (2022). *Front. Cell Dev. Biol.* 9:784983. doi: [10.3389/fcell.2021.784983](https://doi.org/10.3389/fcell.2021.784983)

Due to a publishing error, the symbol which displays first co-authorship for authors Sen Guo, XinYi Wu, and Ting Lei was missing.

The publisher apologizes for the mistake. The original article has been updated.